Biomarin Pharmaceutical Stock Price History
| BMRN Stock | USD 64.26 0.81 1.28% |
Below is the normalized historical share price chart for Biomarin Pharmaceutical extending back to July 23, 1999. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Biomarin Pharmaceutical stands at 64.26, as last reported on the 24th of November, with the highest price reaching 64.46 and the lowest price hitting 63.78 during the day.
If you're considering investing in Biomarin Stock, it is important to understand the factors that can impact its price. Biomarin Pharmaceutical secures Sharpe Ratio (or Efficiency) of -0.19, which signifies that the company had a -0.19% return per unit of risk over the last 3 months. Biomarin Pharmaceutical exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Biomarin Pharmaceutical's Standard Deviation of 2.53, mean deviation of 1.27, and Risk Adjusted Performance of (0.14) to double-check the risk estimate we provide.
At this time, Biomarin Pharmaceutical's Total Stockholder Equity is very stable compared to the past year. As of the 24th of November 2024, Liabilities And Stockholders Equity is likely to grow to about 7.2 B, while Common Stock Shares Outstanding is likely to drop about 127.6 M. . At this time, Biomarin Pharmaceutical's Price Cash Flow Ratio is very stable compared to the past year. As of the 24th of November 2024, Price Fair Value is likely to grow to 3.99, while Price To Sales Ratio is likely to drop 7.11. Biomarin Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 23rd of July 1999 | 200 Day MA 80.9576 | 50 Day MA 68.2524 | Beta 0.31 |
Biomarin |
Sharpe Ratio = -0.1889
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BMRN |
Estimated Market Risk
| 2.55 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biomarin Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomarin Pharmaceutical by adding Biomarin Pharmaceutical to a well-diversified portfolio.
Price Book 2.2623 | Enterprise Value Ebitda 23.5219 | Price Sales 4.4489 | Shares Float 179.2 M | Wall Street Target Price 98.3859 |
Biomarin Pharmaceutical Stock Price History Chart
There are several ways to analyze Biomarin Stock price data. The simplest method is using a basic Biomarin candlestick price chart, which shows Biomarin Pharmaceutical price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | September 3, 2024 | 91.6 |
| Lowest Price | November 18, 2024 | 61.93 |
Biomarin Pharmaceutical November 24, 2024 Stock Price Synopsis
Various analyses of Biomarin Pharmaceutical's daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Biomarin Stock. It can be used to describe the percentage change in the price of Biomarin Pharmaceutical from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Biomarin Stock.| Biomarin Pharmaceutical Price Daily Balance Of Power | 1.19 | |
| Biomarin Pharmaceutical Price Action Indicator | 0.55 | |
| Biomarin Pharmaceutical Price Rate Of Daily Change | 1.01 |
Biomarin Pharmaceutical November 24, 2024 Stock Price Analysis
Biomarin Stock Price History Data
The price series of Biomarin Pharmaceutical for the period between Mon, Aug 26, 2024 and Sun, Nov 24, 2024 has a statistical range of 29.67 with a coefficient of variation of 12.22. The prices are distributed with arithmetic mean of 73.03. The median price for the last 90 days is 70.1.| Open | High | Low | Close | Volume | ||
11/24/2024 | 63.88 | 64.46 | 63.78 | 64.26 | ||
| 11/22/2024 | 63.88 | 64.46 | 63.78 | 64.26 | 1,304,423 | |
| 11/21/2024 | 62.40 | 63.76 | 61.41 | 63.45 | 1,362,545 | |
| 11/20/2024 | 61.97 | 62.70 | 61.61 | 62.56 | 1,245,521 | |
| 11/19/2024 | 61.57 | 62.03 | 61.15 | 61.97 | 1,893,980 | |
| 11/18/2024 | 63.15 | 63.52 | 61.40 | 61.93 | 2,061,275 | |
| 11/15/2024 | 66.05 | 66.05 | 63.22 | 63.42 | 1,687,358 | |
| 11/14/2024 | 66.37 | 67.00 | 65.53 | 65.60 | 1,389,750 | |
| 11/13/2024 | 66.18 | 67.00 | 66.00 | 66.66 | 1,455,062 | |
| 11/12/2024 | 65.96 | 66.69 | 65.80 | 66.13 | 1,151,634 | |
| 11/11/2024 | 67.21 | 67.95 | 66.33 | 66.37 | 904,810 | |
| 11/08/2024 | 66.76 | 67.44 | 66.67 | 67.07 | 1,052,790 | |
| 11/07/2024 | 66.32 | 67.30 | 65.76 | 66.94 | 1,350,587 | |
| 11/06/2024 | 67.31 | 67.64 | 65.79 | 66.15 | 1,970,160 | |
| 11/05/2024 | 66.23 | 66.23 | 65.45 | 66.04 | 1,613,768 | |
| 11/04/2024 | 66.24 | 66.59 | 65.56 | 66.01 | 2,038,435 | |
| 11/01/2024 | 65.70 | 66.81 | 65.60 | 66.60 | 1,644,379 | |
| 10/31/2024 | 66.68 | 66.92 | 65.35 | 65.89 | 1,843,300 | |
| 10/30/2024 | 69.67 | 69.67 | 65.78 | 66.68 | 2,784,230 | |
| 10/29/2024 | 69.78 | 70.56 | 69.20 | 69.91 | 1,845,674 | |
| 10/28/2024 | 69.92 | 70.71 | 69.60 | 70.13 | 1,543,995 | |
| 10/25/2024 | 70.68 | 70.98 | 69.66 | 69.73 | 1,059,252 | |
| 10/24/2024 | 70.05 | 70.98 | 69.58 | 70.39 | 1,120,295 | |
| 10/23/2024 | 70.23 | 70.37 | 69.40 | 69.98 | 1,544,509 | |
| 10/22/2024 | 69.72 | 70.74 | 69.50 | 70.53 | 1,219,982 | |
| 10/21/2024 | 69.99 | 70.81 | 69.56 | 70.28 | 1,554,614 | |
| 10/18/2024 | 69.70 | 70.13 | 69.29 | 70.11 | 1,510,073 | |
| 10/17/2024 | 70.28 | 70.28 | 69.34 | 69.47 | 933,323 | |
| 10/16/2024 | 70.24 | 70.90 | 69.94 | 70.16 | 1,429,664 | |
| 10/15/2024 | 70.12 | 70.52 | 69.53 | 70.46 | 1,063,267 | |
| 10/14/2024 | 70.40 | 70.77 | 69.96 | 70.27 | 1,069,633 | |
| 10/11/2024 | 69.64 | 70.58 | 69.25 | 70.35 | 807,249 | |
| 10/10/2024 | 69.80 | 69.88 | 68.95 | 69.85 | 979,379 | |
| 10/09/2024 | 68.95 | 69.95 | 68.34 | 69.80 | 1,553,177 | |
| 10/08/2024 | 69.00 | 69.00 | 68.03 | 68.69 | 1,701,373 | |
| 10/07/2024 | 69.20 | 69.27 | 68.36 | 68.96 | 839,628 | |
| 10/04/2024 | 68.49 | 69.58 | 67.76 | 69.51 | 1,325,614 | |
| 10/03/2024 | 69.58 | 69.81 | 68.10 | 68.16 | 1,396,622 | |
| 10/02/2024 | 69.66 | 69.85 | 68.52 | 69.66 | 1,144,512 | |
| 10/01/2024 | 70.66 | 70.74 | 69.81 | 70.10 | 1,222,449 | |
| 09/30/2024 | 70.58 | 71.24 | 69.91 | 70.29 | 1,426,527 | |
| 09/27/2024 | 70.55 | 71.00 | 70.24 | 70.58 | 1,094,503 | |
| 09/26/2024 | 69.21 | 70.33 | 68.70 | 70.24 | 1,303,532 | |
| 09/25/2024 | 69.03 | 69.54 | 68.12 | 69.02 | 1,702,593 | |
| 09/24/2024 | 69.13 | 69.65 | 67.75 | 69.48 | 2,150,946 | |
| 09/23/2024 | 70.30 | 70.92 | 69.00 | 69.13 | 2,119,147 | |
| 09/20/2024 | 71.82 | 71.82 | 70.09 | 70.69 | 3,398,022 | |
| 09/19/2024 | 71.75 | 72.07 | 70.42 | 71.41 | 2,934,426 | |
| 09/18/2024 | 70.87 | 71.58 | 70.11 | 71.14 | 2,171,466 | |
| 09/17/2024 | 70.00 | 71.64 | 68.83 | 70.55 | 4,649,759 | |
| 09/16/2024 | 77.53 | 78.00 | 69.60 | 69.86 | 10,574,658 | |
| 09/13/2024 | 84.43 | 85.00 | 83.95 | 84.90 | 1,195,484 | |
| 09/12/2024 | 84.83 | 85.00 | 83.91 | 84.38 | 1,488,427 | |
| 09/11/2024 | 84.72 | 84.94 | 83.43 | 84.78 | 1,454,153 | |
| 09/10/2024 | 84.48 | 85.64 | 83.69 | 84.85 | 1,981,585 | |
| 09/09/2024 | 84.28 | 84.84 | 83.45 | 84.33 | 1,686,308 | |
| 09/06/2024 | 85.33 | 86.04 | 83.73 | 84.08 | 1,580,812 | |
| 09/05/2024 | 90.01 | 90.01 | 84.89 | 85.12 | 2,445,580 | |
| 09/04/2024 | 91.19 | 92.05 | 87.68 | 89.86 | 3,742,096 | |
| 09/03/2024 | 91.21 | 92.81 | 90.85 | 91.60 | 1,979,350 | |
| 08/30/2024 | 91.46 | 92.35 | 89.95 | 91.21 | 1,369,401 |
About Biomarin Pharmaceutical Stock history
Biomarin Pharmaceutical investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Biomarin is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Biomarin Pharmaceutical will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Biomarin Pharmaceutical stock prices may prove useful in developing a viable investing in Biomarin Pharmaceutical
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 191.6 M | 127.6 M | |
| Net Income Applicable To Common Shares | 162.8 M | 170.9 M |
Biomarin Pharmaceutical Quarterly Net Working Capital |
|
Biomarin Pharmaceutical Stock Technical Analysis
Biomarin Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Biomarin Pharmaceutical Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Biomarin Pharmaceutical's price direction in advance. Along with the technical and fundamental analysis of Biomarin Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Biomarin to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (1.12) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.607 | Earnings Share 1.66 | Revenue Per Share 14.529 | Quarterly Revenue Growth 0.283 | Return On Assets 0.03 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.